Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.
Anti-TNFalpha therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.
Hyrich
K L
KL
ARC Epidemiology Unit, University of Manchester, Oxford Road, Manchester M13 9PT, UK.
Silman
A J
AJ
Watson
K D
KD
Symmons
D P M
DP
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001327:Autoimmune Diseases / Q000139:chemically induced; D000068800:Etanercept; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D000069285:Infliximab; D009894:Opportunistic Infections / Q000139:chemically induced; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept